News Image

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Provided By GlobeNewswire

Last update: May 2, 2025

WESTLAKE VILLAGE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 26,500 restricted stock units of Arcutis’ common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of May 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more at globenewswire.com

ARCUTIS BIOTHERAPEUTICS INC

NASDAQ:ARQT (8/5/2025, 8:00:00 PM)

After market: 15.4 +0.08 (+0.49%)

15.325

+0.8 (+5.54%)



Find more stocks in the Stock Screener

Follow ChartMill for more